PWA
AKBA icon

Physician Wealth Advisors’s Akebia Therapeutics AKBA Stock Holding History

Physician Wealth Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-272
Closed -$743 – 2037
2025
Q3 		$743 Hold
272
– – ﹤0.01% 1715
2025
Q2 		$991 Buy
+272
New +$747 ﹤0.01% 1433

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Physician Wealth Advisors's AKBA Position: Q4 2025 in Review

Physician Wealth Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 272 shares — an estimated $743 sold.

Physician Wealth Advisors first reported a position in AKBA in Q2 2025 and held it in 2 quarters. The position peaked at $991 in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • Physician Wealth Advisors reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Physician Wealth Advisors sold 272 Akebia Therapeutics shares in Q4 2025, an estimated $743.
  • Physician Wealth Advisors first reported a position in Akebia Therapeutics in Q2 2025 and held it in 2 quarters.
  • Physician Wealth Advisors's Akebia Therapeutics position peaked at $991 in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Physician Wealth Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.